Rani Therapeutics Ownership 2024 | Who Owns Rani Therapeutics Now?
Institutional Ownership
3.97%
Insider Ownership
43.90%
Retail Ownership
52.14%
Institutional Holders
15.00
Rani Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
VANGUARD GROUP INC | 2.73% | 0.00% | 709,828 | 24,525 | 3.58% | 2,697,347 | Jun 30, 2024 |
NAN FUNG GROUP HOLDINGS LTD | 1.90% | 2.00% | 493,584 | - | - | 1,875,619 | Jun 30, 2024 |
ALPHABET INC. | 1.72% | 0.09% | 448,492 | - | - | 1,704,270 | Jun 30, 2024 |
UNITED SERVICES AUTOMOBILE ASSOCIATION | 1.20% | 0.03% | 312,095 | -169,205 | -35.16% | 1,185,961 | Jun 30, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | 0.58% | 0.00% | 150,734 | 19,828 | 15.15% | 572,922 | Jun 30, 2024 |
STIFEL FINANCIAL CORP | 0.52% | 0.00% | 134,620 | 2,186 | 1.65% | 511,556 | Jun 30, 2024 |
BANK OF AMERICA CORP /DE/ | 0.35% | - | 91,846 | -32,659 | -26.23% | 349,015 | Jun 30, 2024 |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.27% | 0.01% | 71,500 | 20,000 | 38.84% | 271,700 | Jun 30, 2024 |
BLACKROCK INC. | 0.24% | - | 63,583 | - | - | 241,615 | Jun 30, 2024 |
LASRY MARC | 0.24% | 0.24% | 62,887 | - | - | 238,971 | Jun 30, 2024 |
KING LUTHER CAPITAL MANAGEMENT CORP | 0.22% | 0.00% | 56,129 | - | - | 213,290 | Jun 30, 2024 |
MOTCO | 0.18% | 0.01% | 48,129 | - | - | 182,890 | Jun 30, 2024 |
STATE STREET CORP | 0.16% | - | 42,042 | 8,300 | 24.60% | 159,760,000 | Jun 30, 2024 |
NORTHERN TRUST CORP | 0.14% | - | 35,306 | 9,318 | 35.85% | 134,163,000 | Jun 30, 2024 |
BROWN ADVISORY INC | 0.13% | 0.00% | 32,911 | -1,000 | -2.95% | 125,062 | Jun 30, 2024 |
BELVEDERE TRADING LLC | 0.12% | 0.00% | 30,800 | 30,800 | 100.00% | 117,040 | Jun 30, 2024 |
RENAISSANCE TECHNOLOGIES LLC | 0.08% | 0.00% | 21,700 | -48,600 | -69.13% | 82,460 | Jun 30, 2024 |
MARSHALL WACE, LLP | 0.08% | 0.00% | 21,247 | 21,247 | 100.00% | 80,739 | Jun 30, 2024 |
LAFAYETTE INVESTMENTS, INC. | 0.08% | 0.02% | 19,893 | - | - | 75,594 | Jun 30, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.06% | 0.00% | 14,437 | 13,198 | 1065.21% | 54,861 | Jun 30, 2024 |
Rani Therapeutics's largest institutional shareholder is VANGUARD GROUP INC, holding 2.73% of the company's total share outstanding, currently valued at $2.70M. The top 10 institutional shareholders own together 9.75% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
NAN FUNG GROUP HOLDINGS LTD | 1.90% | 2.00% | 493,584 | - | - | 1,875,619 | Jun 30, 2024 |
LASRY MARC | 0.24% | 0.24% | 62,887 | - | - | 238,971 | Jun 30, 2024 |
ALPHABET INC. | 1.72% | 0.09% | 448,492 | - | - | 1,704,270 | Jun 30, 2024 |
UNITED SERVICES AUTOMOBILE ASSOCIATION | 1.20% | 0.03% | 312,095 | -169,205 | -35.16% | 1,185,961 | Jun 30, 2024 |
ISLAY CAPITAL MANAGEMENT, LLC | 0.04% | 0.03% | 9,611 | - | - | 36,522 | Jun 30, 2024 |
LAFAYETTE INVESTMENTS, INC. | 0.08% | 0.02% | 19,893 | - | - | 75,594 | Jun 30, 2024 |
MOTCO | 0.18% | 0.01% | 48,129 | - | - | 182,890 | Jun 30, 2024 |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.27% | 0.01% | 71,500 | 20,000 | 38.84% | 271,700 | Jun 30, 2024 |
VIRTU FINANCIAL LLC | 0.04% | 0.00% | 10,153 | 10,153 | 100.00% | 39,000 | Jun 30, 2024 |
KING LUTHER CAPITAL MANAGEMENT CORP | 0.22% | 0.00% | 56,129 | - | - | 213,290 | Jun 30, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.06% | 0.00% | 14,437 | 13,198 | 1065.21% | 54,861 | Jun 30, 2024 |
PRIME CAPITAL INVESTMENT ADVISORS, LLC | 0.05% | 0.00% | 13,882 | - | - | 52,752 | Jun 30, 2024 |
STIFEL FINANCIAL CORP | 0.52% | 0.00% | 134,620 | 2,186 | 1.65% | 511,556 | Jun 30, 2024 |
BROWN ADVISORY INC | 0.13% | 0.00% | 32,911 | -1,000 | -2.95% | 125,062 | Jun 30, 2024 |
BELVEDERE TRADING LLC | 0.12% | 0.00% | 30,800 | 30,800 | 100.00% | 117,040 | Jun 30, 2024 |
RENAISSANCE TECHNOLOGIES LLC | 0.08% | 0.00% | 21,700 | -48,600 | -69.13% | 82,460 | Jun 30, 2024 |
MARSHALL WACE, LLP | 0.08% | 0.00% | 21,247 | 21,247 | 100.00% | 80,739 | Jun 30, 2024 |
ALLWORTH FINANCIAL LP | 0.01% | 0.00% | 3,119 | - | - | 9,607 | Jun 30, 2024 |
VANGUARD GROUP INC | 2.73% | 0.00% | 709,828 | 24,525 | 3.58% | 2,697,347 | Jun 30, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | 0.58% | 0.00% | 150,734 | 19,828 | 15.15% | 572,922 | Jun 30, 2024 |
The largest Rani Therapeutics shareholder by % of total assets is NAN FUNG GROUP HOLDINGS LTD. The company owns 493.58K shares of Rani Therapeutics (RANI), representing 2.00% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BELVEDERE TRADING LLC | 0.12% | 0.00% | 30,800 | 30,800 | 100.00% | 117,040 | Jun 30, 2024 |
VANGUARD GROUP INC | 2.73% | 0.00% | 709,828 | 24,525 | 3.58% | 2,697,347 | Jun 30, 2024 |
MARSHALL WACE, LLP | 0.08% | 0.00% | 21,247 | 21,247 | 100.00% | 80,739 | Jun 30, 2024 |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.27% | 0.01% | 71,500 | 20,000 | 38.84% | 271,700 | Jun 30, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | 0.58% | 0.00% | 150,734 | 19,828 | 15.15% | 572,922 | Jun 30, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.06% | 0.00% | 14,437 | 13,198 | 1065.21% | 54,861 | Jun 30, 2024 |
VIRTU FINANCIAL LLC | 0.04% | 0.00% | 10,153 | 10,153 | 100.00% | 39,000 | Jun 30, 2024 |
NORTHERN TRUST CORP | 0.14% | - | 35,306 | 9,318 | 35.85% | 134,163,000 | Jun 30, 2024 |
STATE STREET CORP | 0.16% | - | 42,042 | 8,300 | 24.60% | 159,760,000 | Jun 30, 2024 |
STIFEL FINANCIAL CORP | 0.52% | 0.00% | 134,620 | 2,186 | 1.65% | 511,556 | Jun 30, 2024 |
BELVEDERE TRADING LLC | 0.00% | - | 1,100 | 1,100 | 100.00% | 4,180 | Jun 30, 2024 |
BELVEDERE TRADING LLC | 0.00% | - | 991 | 991 | 100.00% | 3,766 | Jun 30, 2024 |
MORGAN STANLEY | 0.01% | - | 2,951 | 500 | 20.40% | 11,214 | Jun 30, 2024 |
SIMPLEX TRADING, LLC | 0.01% | - | 1,482 | 118 | 8.65% | 5,000 | Jun 30, 2024 |
QUBE RESEARCH & TECHNOLOGIES LTD | - | - | 3 | - | - | 12 | Jun 30, 2024 |
RHUMBLINE ADVISERS | 0.00% | - | 312 | - | - | 1,185 | Jun 30, 2024 |
UBS GROUP AG | 0.01% | - | 3,000 | - | - | 11,400 | Jun 30, 2024 |
BLACKROCK INC. | 0.24% | - | 63,583 | - | - | 241,615 | Jun 30, 2024 |
ALLWORTH FINANCIAL LP | 0.01% | 0.00% | 3,119 | - | - | 9,607 | Jun 30, 2024 |
PRIME CAPITAL INVESTMENT ADVISORS, LLC | 0.05% | 0.00% | 13,882 | - | - | 52,752 | Jun 30, 2024 |
As of Jun 30 2024, Rani Therapeutics's largest institutional buyer is BELVEDERE TRADING LLC. The company purchased 30.80K stocks of RANI, valued at $117.04K.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
UNITED SERVICES AUTOMOBILE ASSOCIATION | 1.20% | 0.03% | 312,095 | -169,205 | -35.16% | 1,185,961 | Jun 30, 2024 |
RENAISSANCE TECHNOLOGIES LLC | 0.08% | 0.00% | 21,700 | -48,600 | -69.13% | 82,460 | Jun 30, 2024 |
ALPHA SQUARE GROUP S, LLC | - | - | - | -33,401 | -100.00% | - | Jun 30, 2024 |
BANK OF AMERICA CORP /DE/ | 0.35% | - | 91,846 | -32,659 | -26.23% | 349,015 | Jun 30, 2024 |
XR SECURITIES LLC | - | - | - | -30,900 | -100.00% | - | Jun 30, 2024 |
HRT FINANCIAL LP | - | - | - | -22,587 | -100.00% | - | Jun 30, 2024 |
CHOREO, LLC | - | - | - | -19,813 | -100.00% | - | Jun 30, 2024 |
JPMORGAN CHASE & CO | 0.00% | - | 71 | -12,615 | -99.44% | 270 | Jun 30, 2024 |
ACTIVEST WEALTH MANAGEMENT | - | - | - | -9,800 | -100.00% | - | Jun 30, 2024 |
PNC FINANCIAL SERVICES GROUP, INC. | 0.01% | - | 2,000 | -7,116 | -78.06% | 7,600 | Jun 30, 2024 |
BROWN ADVISORY INC | 0.13% | 0.00% | 32,911 | -1,000 | -2.95% | 125,062 | Jun 30, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -103 | -100.00% | - | Jun 30, 2024 |
NAN FUNG GROUP HOLDINGS LTD | 1.90% | 2.00% | 493,584 | - | - | 1,875,619 | Jun 30, 2024 |
LASRY MARC | 0.24% | 0.24% | 62,887 | - | - | 238,971 | Jun 30, 2024 |
ALPHABET INC. | 1.72% | 0.09% | 448,492 | - | - | 1,704,270 | Jun 30, 2024 |
ISLAY CAPITAL MANAGEMENT, LLC | 0.04% | 0.03% | 9,611 | - | - | 36,522 | Jun 30, 2024 |
LAFAYETTE INVESTMENTS, INC. | 0.08% | 0.02% | 19,893 | - | - | 75,594 | Jun 30, 2024 |
MOTCO | 0.18% | 0.01% | 48,129 | - | - | 182,890 | Jun 30, 2024 |
KING LUTHER CAPITAL MANAGEMENT CORP | 0.22% | 0.00% | 56,129 | - | - | 213,290 | Jun 30, 2024 |
PRIME CAPITAL INVESTMENT ADVISORS, LLC | 0.05% | 0.00% | 13,882 | - | - | 52,752 | Jun 30, 2024 |
As of Jun 30 2024, Rani Therapeutics's biggest institutional seller is UNITED SERVICES AUTOMOBILE ASSOCIATION. The company sold -0.17M shares of RANI, valued at $1.19M.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BELVEDERE TRADING LLC | 0.12% | 0.00% | 30,800 | 30,800 | 100.00% | 117,040 | Jun 30, 2024 |
MARSHALL WACE, LLP | 0.08% | 0.00% | 21,247 | 21,247 | 100.00% | 80,739 | Jun 30, 2024 |
VIRTU FINANCIAL LLC | 0.04% | 0.00% | 10,153 | 10,153 | 100.00% | 39,000 | Jun 30, 2024 |
BELVEDERE TRADING LLC | 0.00% | - | 1,100 | 1,100 | 100.00% | 4,180 | Jun 30, 2024 |
BELVEDERE TRADING LLC | 0.00% | - | 991 | 991 | 100.00% | 3,766 | Jun 30, 2024 |
Rani Therapeutics's largest new institutional shareholder by number of shares is BELVEDERE TRADING LLC, purchased 30.80K shares, valued at $117.04K, as of undefined.
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ALPHA SQUARE GROUP S, LLC | - | - | - | -33,401 | -100.00% | - | Jun 30, 2024 |
XR SECURITIES LLC | - | - | - | -30,900 | -100.00% | - | Jun 30, 2024 |
HRT FINANCIAL LP | - | - | - | -22,587 | -100.00% | - | Jun 30, 2024 |
CHOREO, LLC | - | - | - | -19,813 | -100.00% | - | Jun 30, 2024 |
ACTIVEST WEALTH MANAGEMENT | - | - | - | -9,800 | -100.00% | - | Jun 30, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -103 | -100.00% | - | Jun 30, 2024 |
Rani Therapeutics's largest sold out institutional shareholder by shares sold is ALPHA SQUARE GROUP S, LLC, sold -33.40K shares, valued at -, as of undefined.
Rani Therapeutics Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
VANGUARD VALLEY FORGE FUNDS | 0.03% | 17,809 | - | - | Mar 31, 2024 |
BRIDGEWAY FUNDS INC | 0.02% | 51,500 | - | - | Mar 28, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 667,153 | -78,921 | -10.58% | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 124,026 | 16,753 | 15.62% | Feb 29, 2024 |
VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 14,248 | - | - | Mar 31, 2024 |
SCHWAB CAPITAL TRUST | 0.00% | 2,793 | - | - | Feb 29, 2024 |
NATIONWIDE MUTUAL FUNDS | 0.00% | 3,944 | 3,944 | - | Jan 31, 2024 |
VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 280 | - | - | Mar 31, 2024 |
Goldman Sachs ETF Trust | 0.00% | 2,119 | - | - | Feb 29, 2024 |
PROSHARES TRUST | 0.00% | 2,060 | - | - | Feb 29, 2024 |
USAA MUTUAL FUNDS TRUST | 0.00% | 1,880 | - | - | Jan 31, 2024 |
iSHARES TRUST | 0.00% | 127,073 | - | - | Mar 31, 2024 |
VANGUARD SCOTTSDALE FUNDS | 0.00% | 3,926 | - | - | Feb 29, 2024 |
Invesco Exchange-Traded Fund Trust II | 0.00% | 453 | - | - | Jan 31, 2024 |
GOLDMAN SACHS TRUST | 0.00% | 4,103 | - | - | Mar 31, 2024 |
JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 594 | - | - | Mar 31, 2024 |
Rani Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 17.81K shares, compromising 0.03% of its total assets.
Rani Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
30 Jun, 24 | 15 | -59.46% |
31 Mar, 24 | 37 | 15.63% |
31 Dec, 23 | 32 | -3.03% |
30 Sep, 23 | 33 | -8.33% |
30 Jun, 23 | 36 | -2.70% |
31 Mar, 23 | 37 | 8.82% |
31 Dec, 22 | 34 | 6.25% |
30 Sep, 22 | 32 | 18.52% |
30 Jun, 22 | 27 | 17.39% |
31 Mar, 22 | 23 | 9.52% |
31 Dec, 21 | 21 | 40.00% |
30 Sep, 21 | 15 | - |
As of 30 Jun 24, 15 institutions are holding Rani Therapeutics's shares, representing a decrease of -59.46% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
30 Jun, 24 | 1,032,982 | -66.84% |
31 Mar, 24 | 3,115,105 | 5.54% |
31 Dec, 23 | 2,951,624 | -8.01% |
30 Sep, 23 | 3,208,534 | -0.58% |
30 Jun, 23 | 3,227,286 | 7.60% |
31 Mar, 23 | 2,999,366 | 1.73% |
31 Dec, 22 | 2,948,381 | -7.13% |
30 Sep, 22 | 3,174,625 | 12.37% |
30 Jun, 22 | 2,825,035 | 10.49% |
31 Mar, 22 | 2,556,816 | 106.04% |
31 Dec, 21 | 1,240,939 | 13.05% |
30 Sep, 21 | 1,097,738 | - |
Rani Therapeutics (RANI) has 1.03M shares outstanding as of 30 Jun 24, down -66.84% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
30 Jun, 24 | 3.97% | 2.66% |
31 Mar, 24 | 12.21% | 9.15% |
31 Dec, 23 | 11.55% | 7.21% |
30 Sep, 23 | 12.66% | 7.74% |
30 Jun, 23 | 12.79% | 9.05% |
31 Mar, 23 | 11.88% | 8.48% |
31 Dec, 22 | 11.84% | 7.03% |
30 Sep, 22 | 12.97% | 9.66% |
30 Jun, 22 | 11.59% | 8.13% |
31 Mar, 22 | 11.94% | 29.30% |
31 Dec, 21 | 6.38% | 20.02% |
30 Sep, 21 | 5.65% | - |
As of 30 Jun 24, Rani Therapeutics is held by 3.97% institutional shareholders, representing a 2.66% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
30 Jun, 24 | 4 | -66.67% |
31 Mar, 24 | 12 | 140.00% |
31 Dec, 23 | 5 | -44.44% |
30 Sep, 23 | 9 | -43.75% |
30 Jun, 23 | 16 | 6.67% |
31 Mar, 23 | 15 | - |
31 Dec, 22 | 15 | -6.25% |
30 Sep, 22 | 16 | 23.08% |
30 Jun, 22 | 13 | 18.18% |
31 Mar, 22 | 11 | -26.67% |
31 Dec, 21 | 15 | - |
30 Sep, 21 | 15 | - |
4 institutional shareholders have increased their position in RANI stock as of 30 Jun 24 compared to 12 in the previous quarter (a -66.67% decrease).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
30 Jun, 24 | 3 | -40.00% |
31 Mar, 24 | 5 | -16.67% |
31 Dec, 23 | 6 | -14.29% |
30 Sep, 23 | 7 | 250.00% |
30 Jun, 23 | 2 | -50.00% |
31 Mar, 23 | 4 | -50.00% |
31 Dec, 22 | 8 | - |
30 Sep, 22 | 8 | 33.33% |
30 Jun, 22 | 6 | -14.29% |
31 Mar, 22 | 7 | 250.00% |
31 Dec, 21 | 2 | - |
30 Sep, 21 | - | - |
3 institutional shareholders have reduced their position in RANI stock as of 30 Jun 24 compared to 5 in the previous quarter (a -40.00% decrease).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
30 Jun, 24 | 15 | -59.46% | 1,032,982 | -66.84% | 3.97% | 2.66% | 4 | -66.67% | 3 | -40.00% |
31 Mar, 24 | 37 | 15.63% | 3,115,105 | 5.54% | 12.21% | 9.15% | 12 | 140.00% | 5 | -16.67% |
31 Dec, 23 | 32 | -3.03% | 2,951,624 | -8.01% | 11.55% | 7.21% | 5 | -44.44% | 6 | -14.29% |
30 Sep, 23 | 33 | -8.33% | 3,208,534 | -0.58% | 12.66% | 7.74% | 9 | -43.75% | 7 | 250.00% |
30 Jun, 23 | 36 | -2.70% | 3,227,286 | 7.60% | 12.79% | 9.05% | 16 | 6.67% | 2 | -50.00% |
31 Mar, 23 | 37 | 8.82% | 2,999,366 | 1.73% | 11.88% | 8.48% | 15 | - | 4 | -50.00% |
31 Dec, 22 | 34 | 6.25% | 2,948,381 | -7.13% | 11.84% | 7.03% | 15 | -6.25% | 8 | - |
30 Sep, 22 | 32 | 18.52% | 3,174,625 | 12.37% | 12.97% | 9.66% | 16 | 23.08% | 8 | 33.33% |
30 Jun, 22 | 27 | 17.39% | 2,825,035 | 10.49% | 11.59% | 8.13% | 13 | 18.18% | 6 | -14.29% |
31 Mar, 22 | 23 | 9.52% | 2,556,816 | 106.04% | 11.94% | 29.30% | 11 | -26.67% | 7 | 250.00% |
31 Dec, 21 | 21 | 40.00% | 1,240,939 | 13.05% | 6.38% | 20.02% | 15 | - | 2 | - |
30 Sep, 21 | 15 | - | 1,097,738 | - | 5.65% | - | 15 | - | - | - |
Rani Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Open Market Insider Buys
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Insider Sells
All Insider Owners Trades
The last insider sell of Rani Therapeutics's stock was made by Sanford Svai S on Dec 19 2023, selling 83,724 shares at $9.44 per share (valued at $790.35K).
Rani Therapeutics Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2024 | 7 | - | - |
Q1 2024 | 5 | - | - |
Q4 2023 | 34 | 27 | 125.93% |
Q3 2023 | - | - | - |
Q2 2023 | 27 | - | - |
Q1 2023 | 29 | 4 | 725.00% |
Q4 2022 | 31 | - | - |
Q3 2022 | 2 | 4 | 50.00% |
Q2 2022 | 10 | - | - |
Q1 2022 | 13 | 7 | 185.71% |
Q4 2021 | 1 | 1 | 100.00% |
Q3 2021 | 6 | 36 | 16.67% |
7 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Rani Therapeutics's insiders, as of Q2 2024.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2024 | - | - | - |
Q1 2024 | - | - | - |
Q4 2023 | 8 | 1 | 800.00% |
Q3 2023 | - | - | - |
Q2 2023 | 19 | - | - |
Q1 2023 | 21 | - | - |
Q4 2022 | 31 | - | - |
Q3 2022 | - | 2 | - |
Q2 2022 | - | - | - |
Q1 2022 | - | - | - |
Q4 2021 | - | - | - |
Q3 2021 | 3 | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Rani Therapeutics's stocks.
Rani Therapeutics Peer Ownership
Ticker | Company |
---|---|
PMVP | PMV Pharmaceuticals, Inc. |
MNPR | Monopar Therapeutics Inc. |
EYPT | EyePoint Pharmaceuticals, Inc. |
BMEA | Biomea Fusion, Inc. |
TNYA | Tenaya Therapeutics, Inc. |
CRVS | Corvus Pharmaceuticals, Inc. |
SRZN | Surrozen, Inc. |
ALXO | ALX Oncology Holdings Inc. |
SQZ | SQZ Biotechnologies Company |
VIRX | Viracta Therapeutics, Inc. |
TYRA | Tyra Biosciences, Inc. |
CABA | Cabaletta Bio, Inc. |
VCNX | Vaccinex, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
PHVS | Pharvaris N.V. |
VINC | Vincerx Pharma, Inc. |
TARA | Protara Therapeutics, Inc. |
TRVI | Trevi Therapeutics, Inc. |
MOLN | Molecular Partners AG |
LYRA | Lyra Therapeutics, Inc. |
RANI Ownership FAQ
Who Owns Rani Therapeutics?
Rani Therapeutics is owned by institutional shareholders (3.97%), insiders (43.90%), and public (52.14%). The largest institutional shareholder of Rani Therapeutics is VANGUARD GROUP INC (2.73% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.03% of total shares).
Who are the major institutional shareholders of Rani Therapeutics?
Rani Therapeutics's major institutional shareholders are VANGUARD GROUP INC, NAN FUNG GROUP HOLDINGS LTD, ALPHABET INC., UNITED SERVICES AUTOMOBILE ASSOCIATION, and GEODE CAPITAL MANAGEMENT, LLC. The top five shareholders own together 8.12% of the company's share outstanding.
How many Rani Therapeutics shareholders are there?
As of Jun 2024, there are 15 institutional shareholders of Rani Therapeutics.
What percentage of Rani Therapeutics is owned by VANGUARD GROUP INC?
VANGUARD GROUP INC owns 709.83K shares of Rani Therapeutics, representing 2.73% of the company's total shares outstanding, valued at $2.7M (as of Jun 2024).
What percentage of Rani Therapeutics is owned by NAN FUNG GROUP HOLDINGS LTD?
As of Jun 2024, NAN FUNG GROUP HOLDINGS LTD holds 493.58K shares of Rani Therapeutics (RANI), compromising 1.90% of the company, valued at $1.88M.
What percentage of Rani Therapeutics is owned by ALPHABET INC?
ALPHABET INC is the third largest holder of Rani Therapeutics. The company owns 448.49K of the company's shares outstanding (worth $1.7M).